GLOW vs GHK-Cu: preparation and route
The ingredient name can stay familiar while the experiment changes completely. A cream, a hair formulation and a blend each deserve their own account.
Preparation and route
My comparison starts with the material used and how it reached the tissue. The topical review examines skin formulations and their delivery obstacles. The review of unapproved peptide therapies considers a much wider research landscape. Placing the names in adjacent columns can conceal that difference unless the preparation stays visible.
| Preparation | Research setting | What remains unresolved |
|---|---|---|
| GHK-Cu in topical formulations | Small human skin studies, cell work and excised-skin delivery experiments | Finished-formulation performance; broader and longer human trials |
| Injectable or systemic GHK-Cu | Preclinical research; no validated human pharmacokinetic profile | Human distribution, clearance and long-term safety |
| GLOW: GHK-Cu with BPC-157 and TB-500 | Constituent studies across different species, tissues and preparations | Controlled combination outcomes, interactions, stability and pharmacokinetics |
These distinctions also explain why the skin-penetration experiment gets so much space here. An intact skin barrier, a prepared skin layer and an open animal wound create different experimental conditions.
GHK hair trial
A 6-month trial in 45 men with androgenetic alopecia tested a topical complex of 5-aminolevulinic acid and GHK. The study's 100 mg/mL formulation increased hair count by 52.6; its 50 mg/mL formulation by 71.5, compared with 9.6 for placebo. No adverse events were reported in any group. These concentrations describe the study formulations.
I rank the controlled hair-count comparison above a collection of hair-regrowth anecdotes. Attribution still needs restraint: the tested material combined GHK with 5-aminolevulinic acid. It supplies evidence for that combination. It cannot isolate a GHK-Cu effect or answer a question about the GLOW blend.
Cosmetics, medicines and sport
GHK-Cu has a legal topical cosmetic role, while its systemic use is unapproved. There is no approved therapeutic GHK-Cu indication. GLOW has no FDA approval, and both BPC-157 and TB-500 are WADA-prohibited at all times. FDA records BPC-157's compounding nomination as withdrawn but retains its safety warnings; a withdrawal does not establish permission to compound. The peptide-therapy review and BPC-157 review discuss the scientific evidence and anti-doping concerns.
GHK-Cu is not named individually on the WADA list in the source record, though the S0 category can cover non-approved pharmacological substances. A cosmetic ingredient's status leaves the wider route and sporting questions open. The applicable current rules require checking with the relevant anti-doping authority.
The experiment still missing
For GLOW, I want a trial pitting the actual combination against its individual constituents, with composition, route and adverse events documented. That would begin to test the reason for combining them. For topical GHK-Cu, reproducible results from a clearly specified formulation on living human skin would come first. Those are different research tasks, even when a search result puts both under the same promise of better skin.